As some orphan drugs – and their market dynamics – continue to more closely resemble those of mainstream pharmaceuticals, it begs the question: should they still be considered a class apart?

In this webinar, our expert panel will look at the state of the rare disease market and Evaluate’s forecasts for orphan drugs out to 2030.